-
公开(公告)号：US20170227555A1
公开(公告)日：2017-08-10
申请号：US15436585
申请日：2017-02-17
发明人： Daniel M. Ratner , Jill M. Johnsen , James T. Kirk , José A. López , Norman D. Brault , Shaoyi Jiang
IPC分类号： G01N33/80 , G01N21/77 , G01N33/543
CPC分类号： G01N33/54373 , G01N21/75 , G01N33/80
摘要： Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.
-
公开(公告)号：US20160169866A1
公开(公告)日：2016-06-16
申请号：US14906242
申请日：2014-07-21
CPC分类号： G01N33/492 , G01N33/5308 , G01N33/80 , G01N2800/7066 , G16B35/00 , G16C20/60
摘要： Compositions and methods determines post-transfusion survival of platelets and the suitability of platelet units for transfusion by measuring the levels of one or more markers in a platelet sample. A method determines post-transfusion survival of platelets (PL T) prior to transfusion, the method comprising the steps of: a) measuring the levels of one or more markers in a PL T sample selected from the group consisting of adenine, 13-HODE/9-HODE, Caprylate, Laurate, C-glycosyltryptophan, andro steroid monsulfate 2, and Unelucidated Compounds (UC) 1-4; b) comparing the level of the one or more markers in the PLT sample with the level of the one or more markers present in a control sample, wherein a higher or lower level of the one or more markers in the PL T sample is indicative of post-transfusion survival of platelets.
摘要翻译： 组合物和方法通过测量血小板样品中一种或多种标记物的水平来确定血小板的输血后存活和血小板单位适用于输血。 一种方法确定在输血前血小板（PL T）的输血后存活，所述方法包括以下步骤：a）测量PLT样品中一种或多种标记物的水平，所述PLT样品选自腺嘌呤，13-HODE / 9-HODE，辛酸盐，月桂酸盐，C-糖基色氨酸，类固醇甾类单硫酸盐2和未化合化合物（UC）1-4; b）将PLT样品中的一种或多种标记物的水平与对照样品中存在的一种或多种标志物的水平进行比较，其中PL T样品中的一种或多种标记物的较高或较低水平表示 输血后血小板存活。
-
公开(公告)号：US09696305B2
公开(公告)日：2017-07-04
申请号：US14354476
申请日：2012-10-31
发明人： Kathleen Pratt , Kenneth B. Lewis
IPC分类号： G01N31/00 , G01N33/53 , G01N33/564 , G01N33/543 , G01N33/86
CPC分类号： G01N33/48735 , A61K49/00 , B82Y30/00 , C12Q1/00 , G01N33/48 , G01N33/483 , G01N33/5306 , G01N33/54373 , G01N33/564 , G01N33/86 , G06F19/18 , G06F19/24
摘要： Disclosed herein are methods, systems, mediums, and kits for use in phenotyping antibody responses via devices such as surface plasmon resonance devices. Such phenotypes can include total target-specific antibody titers, quantitative isotype distribution of the target-specific antibodies, and/or epitope specificity of the target-specific antibodies. Other methods, systems, mediums, and kits are also disclosed.
-
公开(公告)号：US09638687B2
公开(公告)日：2017-05-02
申请号：US14012885
申请日：2013-08-28
CPC分类号： G01N33/80 , G01N33/5005 , G01N33/53 , G01N2800/7066
摘要： Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.
-
公开(公告)号：US20150320909A1
公开(公告)日：2015-11-12
申请号：US14442387
申请日：2013-11-12
发明人： Dominic Chung , Jose Aron Lopez , Minhua Ling , Junmei Chen , Xiaoyun Fu
IPC分类号： A61L29/14 , A61L29/08 , C07K14/775 , A61L31/14 , A61L31/16 , A61L31/10 , C07K14/755 , A61L29/04
CPC分类号： A61K9/0019 , A61K38/00 , A61K47/42 , A61L29/048 , A61L29/085 , A61L29/143 , A61L29/16 , A61L31/10 , A61L31/143 , A61L31/16 , A61L2300/424 , A61L2400/18 , C07K14/755 , C07K14/775 , Y02A50/411
摘要： Compositions and methods are described for preventing or reducing protein loss due to protein aggregation, denaturation, and absorption to surfaces. Also described are compositions and methods for preventing or reducing the fouling or clogging of medical devices that come into contact with blood, such as catheters. Also described are methods to treat diseases caused by activation of the microvasculature.
摘要翻译： 描述了用于预防或减少由于蛋白质聚集，变性和对表面吸收引起的蛋白质损失的组合物和方法。 还描述了用于防止或减少与血液接触的医疗装置（例如导管）的结垢或堵塞的组合物和方法。 还描述了治疗由微血管活化引起的疾病的方法。
-
6.发明申请METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY 审中-公开降低因子VIII治疗个体因子VIII的免疫原性的方法公开(公告)号：US20140370035A1
公开(公告)日：2014-12-18
申请号：US14371931
申请日：2013-01-12
CPC分类号： C12Q1/6883 , A61K38/21 , A61K38/37 , A61K39/0008 , A61K47/6811 , A61K47/6815 , A61K2039/6031 , A61K2039/6056 , C07K14/755 , C07K2319/30 , C12Q2600/156 , A61K2300/00
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
摘要翻译： 本公开提供了将具有FVIII和Fc的嵌合和杂合因子VIII（FVIII）多肽施用于具有发展抑制性FVIII免疫应答风险的受试者的方法，所述风险包括抗FVIII抗体和/或细胞介导的免疫。 该施用足以促进凝血并诱导对FVIII的免疫耐受。 嵌合多肽可以包含全长FVIII或含有缺失的FVIII多肽，例如B结构域的完整或部分缺失。
-
7.发明授权公开(公告)号：US11286528B2
公开(公告)日：2022-03-29
申请号：US16246225
申请日：2019-01-11
IPC分类号： C07K14/755 , C12Q1/6883 , A61K38/21 , A61K39/00 , A61K38/37 , A61K47/68
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
8.发明授权公开(公告)号：US10221455B2
公开(公告)日：2019-03-05
申请号：US14371931
申请日：2013-01-12
IPC分类号： C07K14/755 , C12Q1/6883 , A61K38/37 , A61K38/21 , A61K39/00 , A61K47/68
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
9.发明申请公开(公告)号：US20230002828A1
公开(公告)日：2023-01-05
申请号：US17681435
申请日：2022-02-25
IPC分类号： C12Q1/6883 , A61K38/21 , A61K39/00 , A61K38/37 , C07K14/755 , A61K47/68
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
10.发明申请公开(公告)号：US20190241960A1
公开(公告)日：2019-08-08
申请号：US16246225
申请日：2019-01-11
IPC分类号： C12Q1/6883 , C07K14/755 , A61K47/68 , A61K39/00 , A61K38/21 , A61K38/37
CPC分类号： C12Q1/6883 , A61K38/21 , A61K38/37 , A61K39/0008 , A61K47/6811 , A61K47/6815 , A61K2039/6031 , A61K2039/6056 , C07K14/755 , C07K2319/30 , C12Q2600/156 , A61K2300/00
摘要： The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.021 秒)
